Clinical Trial Update: Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial of Zalypsis (PM00104) in unresectable or metastatic Ewing family tumors progressed after prior chemotherapy; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Askin Tumor of the Chest Wall
• Ewing Sarcoma
• Extraosseous Ewing Sarcoma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• Zalypsis (PM00104)

Snippet

Sponsor: PharmaMar | Conditions: Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET) | Phase 2 | Status: COMPLETED | Results posted: 2021-10-29